Name | Carboxyamidotriazole Orotate |
Description | Carboxyamidotriazole Orotate (L-651582 Orotate) is a cytostatic inhibitor of non-voltage-operated calcium channels and associated signaling pathways. As the orotate salt form of Carboxyamidotriazole (CAI), it is an orally bioavailable signal transduction inhibitor with in vitro antileukaemic activity, exhibiting anti-tumor, anti-inflammatory, and antiangiogenic effects. |
In vitro | Carboxyamidotriazole Orotate inhibits the phosphorylation of a selected target of Bcr-Abl kinase. Carboxyamidotriazole Orotate (0.1-10 μM; 24-96 hours) inhibits cell proliferation of LAMA84R and K562R cell lines[1]. Tyrosine phosphorylation of CrkL is reduced by 5 μM Carboxyamidotriazole Orotate treatment[1]. |
In vivo | On CML xenografts, Carboxyamidotriazole Orotate (342, 513 mg/kg; i.p.; Q1D×5 for two rounds) shows antitumor activity[1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 5 mg/mL (8.61 mM), Sonication is recommended.
|
Keywords | L651582 | Inhibitor | toxicity | Calcium Channel | L 651582 | Ca2+ channels | Ca channels | leukaemia | inhibit | ovarian | chronic | Carboxyamidotriazole | CAI | Bcr/Abl | L-651582 | cancer | myelogenous | Carboxyamidotriazole Orotate |
Inhibitors Related | Nisoldipine | Nimodipine | 2,5-Di-tert-butylhydroquinone | Diltiazem hydrochloride | Levetiracetam | L-Ascorbic acid | Lanthanum(III) chloride heptahydrate | Butamben | Ethyl cinnamate | 1-Octanol | 1,2,4-Trihydroxybenzene | Otilonium bromide |
Related Compound Libraries | 疼痛相关化合物库 | 经典已知活性库 | 膜蛋白靶向化合物库 | 抗癌临床化合物库 | 药物功能重定位化合物库 | 抑制剂库 | 神经保护化合物库 | 已知活性化合物库 | 离子通道库 | 抗癌药物库 |